Neuroprotection in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine receptor agonist; LRRK2; Mitochondria; Parkinson's disease

Indexed keywords

DNA; GLUCOSYLCERAMIDASE; PLACEBO; PRAMIPEXOLE; RASAGILINE; NEUROPROTECTIVE AGENT;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DNA MODIFICATION; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; GENETICS; PATHOLOGY;

ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 72649084648     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70834-X     Document Type: Article

References (52)

1. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
2. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22 (2008) 1327-1334
3. Chau K.Y., Ching H.L., Schapira A.H., and Cooper J.M. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 110 (2009) 1005-1013
4. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106 (2009) 13010-13015
5. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (2008) 501-503
6. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008) 504-506
7. Olanow C.W., and Prusiner S.B. Is Parkinson's disease a prion disorder?. Proc Natl Acad Sci USA 106 (2009) 12571-12572
8. Narendra D., Tanaka A., Suen D.F., and Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 (2008) 795-803
9. Flinn L., Mortiboys H., Volkmann K., Köster R.W., Ingham P.W., and Bandmann O. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain 132 (2009) 1613-1623
10. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., and Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105 (2008) 1638-1643
11. Deng H., Dodson M.W., Huang H., and Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105 (2008) 14503-14508
12. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006) 1157-1161
13. Gandhi S., Wood-Kaczmar A., Yao Z., Plun-Favreau H., Deas E., Klupsch K., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33 (2009) 627-638
14. Gegg M.E., Cooper J.M., Schapira A.H., and Taanman J.W. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 4 (2009) e4756
15. Grünewald A., Gegg M.E., Taanman J.W., King R.H., Kock N., Klein C., et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol 219 (2009) 266-273
16. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7 (2008) 583-590
17. Tain L.S., Mortiboys H., Tao R.N., Ziviani E., Bandmann O., and Whitworth A.J. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12 (2009) 1129-1135
18. Schapira A.H. Etiology and pathogenesis of Parkinson disease. Neurol Clin 27 (2009) 583-603
19. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
20. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54 (1990) 823-827
21. Morgan-Hughes J.A., Schapira A.H., Cooper J.M., and Clark J.B. Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. J Bioenerg Biomembr 20 (1988) 365-382
22. Morgan-Hughes J.A., Sweeney M.G., Cooper J.M., Hammans S.R., Brockington M., Schapira A.H., et al. Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochim Biophys Acta 1271 (1995) 135-140
23. Schapira A.H. Mitochondrial disease. Lancet 368 (2006) 70-82
24. Cock H.R., Tabrizi S.J., Cooper J.M., and Schapira A.H. The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. Ann Neurol 44 (1998) 187-193
25. Morris A.A., Taanman J.W., Blake J., Cooper J.M., Lake B.D., Malone M., et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 28 (1998) 556-563
26. Schapira A.H. Etiology of Parkinson's disease. Neurology 66 10 Suppl 4 (2006) S10-S23
27. Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N., Chalmers R.M., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364 (2004) 875-882
28. Mancuso M., Filosto M., Oh S.J., and DiMauro S. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism. Arch Neurol 61 (2004) 1777-1779
29. Taanman J.W., and Schapira A.H. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. Neurosci Lett 376 (2005) 56-59
30. Luoma P.T., Eerola J., Ahola S., Hakonen A.H., Hellström O., Kivisto K.T., et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 69 (2007) 1152-1159
31. Warner T.T., and Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S16-S23
32. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., et al. Parkinson disease in twins: an etiologic study. JAMA 281 (1999) 341-346
33. Smith P.R., Cooper J.M., Govan G.G., Harding A.E., and Schapira A.H. Smoking and mitochondrial function: a model for environmental toxins. Q J Med 86 (1993) 657-660
34. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7 (2008) 97-109
35. Owen A.D., Schapira A.H., Jenner P., and Marsden C.D. Oxidative stress and Parkin-son's disease. Ann N Y Acad Sci 786 (1996) 217-223
36. Schapira A.H., Agid Y., Barone P., Jenner P., Lemke M.R., Poewe W., et al. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 16 10 (2009) 1090-1099
37. Seaton T.A., Cooper J.M., and Schapira A.H. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res 809 (1998) 12-17
38. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 72 7 Suppl (2009) S44-S50
39. Schapira A.H., and Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 59 (2006) 559-562
40. Olanow C.W., Kieburtz K., and Schapira A.H. Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann Neurol 64 Suppl 2 (2008) S101-S110
41. Schapira A.H. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 30 (2009) 41-47
42. Schapira A.H. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 15 Suppl 1 (2008) 5-13
43. Schapira A.H. The scientific and clinical basis for future therapies in Parkinson's disease. Eur J Neurol 15 Suppl 1 (2008) v
44. Olanow C.W., Schapira A.H., LeWitt P.A., Kieburtz K., Sauer D., Olivieri G., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
45. Schapira A.H., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5 (2006) 845-854
46. Schapira A.H. Disease modification in Parkinson's disease. Lancet Neurol 3 (2004) 362-368
47. Hart R.G., Pearce L.A., Ravina B.M., Yaltho T.C., and Marler J.R. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 24 (2009) 647-654
48. Schapira A.H. Science, medicine, and the future: Parkinson's disease. BMJ 318 (1999) 311-314
49. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009) 1268-1278
50. Schapira A.H., Hsu H.H., Scrine K., Gordon M.F., and Marek K.L. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Eur J Neurol 15 Suppl 3 (2008) 132P1366
51. Chaudhuri K.R., Healy D.G., and Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 (2006) 235-245
52. Chaudhuri K.R., and Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8 (2009) 464-474